Travere is counting heavily on furthering Filspari as a potential blockbuster in IgAN. For decades, blood pressure medicines were the lone treatment in the indication. This month, Swedish company Calliditas expects to receive full approval for its IgAN drug Tarpeyo, which was approved on an accelerated basis in 2021 and has since posted strong phase 3 data. Some patients may be hesitant to use the corticosteroid however because of the side effects.